Use of thromboprophylaxis in palliative care patients: a survey among experts in palliative care, oncology, intensive care, and anticoagulation

Am J Hosp Palliat Care. 2008 Apr-May;25(2):127-31. doi: 10.1177/1049909107310142. Epub 2008 Jan 15.

Abstract

Study-based guidelines on thromboprophylaxis are not available for palliative care patients. The authors asked a panel of academic medical experts in palliative care, oncology, blood coagulation, and intensive care to select a prophylactic regimen out of 5 predefined options for a virtual patient with advanced bronchial cancer in different clinical settings. Primary prophylaxis for venous thromboembolism was withdrawn by all physicians when the patient had a Karnovsky's index of 10 and was described as dying. It was given by 25% of physicians when the patient had a Karnovsky's index of 20 and by 85% when Karnovsky's index 40 was still 40. Similar results were obtained in the situation of secondary prophylaxis of venous thromboembolism and when the patient was described as having a history of chronic atrial fibrillation. This data clearly show that thromboprophylaxis is delivered according to a compound estimate of risks and benefits of such prophylaxis in a specific palliative care situation.

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / etiology
  • Atrial Fibrillation / prevention & control
  • Attitude of Health Personnel*
  • Austria
  • Bronchial Neoplasms / complications
  • Critical Care / methods*
  • Female
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Guideline Adherence
  • Humans
  • Karnofsky Performance Status
  • Male
  • Medical Oncology / methods*
  • Middle Aged
  • Palliative Care / methods*
  • Patient Selection*
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians'
  • Prognosis
  • Quality of Life
  • Surveys and Questionnaires
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control
  • Withholding Treatment

Substances

  • Anticoagulants
  • Fibrinolytic Agents